Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Gaush Meditech Ltd. ( (HK:2407) ).
Gaush Meditech’s subsidiary Gaush Neotech has obtained a CE registration certificate for its corneal confocal microscope from DEKRA, confirming compliance with the European Union Medical Device Regulation. This certification validates the product’s safety, performance, and lifecycle risk management to EU standards, a key requirement for entry into the European medical device market.
The recognition strengthens Gaush Meditech’s technical credentials and provides a solid basis for expanding into global markets, particularly the high-end ophthalmic segment. By meeting one of the most widely recognized regulatory benchmarks worldwide, the company enhances its international competitiveness and positions itself to leverage high-quality, technologically advanced products to drive overseas growth, though investors are advised to exercise caution when trading its shares.
The most recent analyst rating on (HK:2407) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Gaush Meditech Ltd. stock, see the HK:2407 Stock Forecast page.
More about Gaush Meditech Ltd.
Gaush Meditech Ltd. is a Cayman Islands–incorporated medical technology group focused on ophthalmic medical devices, with a particular emphasis on high-end diagnostic equipment. Through subsidiaries such as Gaush Neotech Ltd., the company targets global markets for advanced eye-care solutions, aiming to compete in the premium segment of the international ophthalmic medical market.
Average Trading Volume: 48,329
Technical Sentiment Signal: Sell
Current Market Cap: HK$761.6M
Find detailed analytics on 2407 stock on TipRanks’ Stock Analysis page.